Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Receives $22.29 Consensus PT from Analysts
Zevra Therapeutics, Inc. (NASDAQ:ZVRA – Get Free Report) has received a consensus rating of “Buy” from the nine ratings firms that are currently covering the company, MarketBeat reports. Eight analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month price target […]
Zevra Therapeutics, Inc. (NASDAQ:ZVRA – Get Free Report) has received a consensus rating of “Buy” from the nine ratings firms that are currently covering the company, MarketBeat reports. Eight analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month price target […]
